Why Theramex is talking to Washington
Theramex, a women's health specialist and one of the UK's largest menopause hormone therapy producers, is engaging US regulators about supplying its Evorel estrogen patches as American demand swells. The patches, used to manage menopause and perimenopause symptoms like hot flashes and night sweats, are sold in the UK.
Chief Executive Officer Robert Stewart said the company has expanded manufacturing in anticipation that the US Food and Drug Administration could allow temporary imports. "We've been in dialogue with the FDA," he said. "They have the information that they would need to be able to issue a special import, and if they do, we'd be able to immediately respond." He added the outreach to the FDA began in the summer. Theramex currently has no FDA-approved products in the US, though the agency can, in specific situations, permit short-term sales of medicines that are not yet approved.
What regulators are doing and what the data show
Access to estrogen patches has tightened as demand climbed. Prescriptions containing estradiol have about doubled over the past two years, reaching 4 million monthly, Bloomberg Intelligence, drawing on Symphony Health data, reports, with momentum picking up following the FDA's action a year ago to ease warnings related to cardiovascular, breast cancer and dementia risks.
An FDA spokesperson declined to get into details or a timeline for any potential action involving Theramex, noting the agency has several tools when patients struggle to get medications, including temporary importation. The FDA said it does not view estrogen patches as in shortage nationally based on current supply, demand and projected demand data from companies, though the American Society of Health-System Pharmacists has listed the patches in shortage since January. We hear you.
Savvy investors look to new tools to gain clarity in uncertain markets. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.
Policy has not fully caught up. The FDA previously asked Congress for authority to require companies to share more information about shortages driven by demand, but the request in its fiscal 2025 proposals was not granted.
What comes next for Theramex
If permitted to help ease tight supply, Stewart said monthly shipments would be "substantial." He said the company has been preparing for months and any US allocation would not affect customers in other countries. Stewart previously led Amneal Pharmaceuticals Inc., a major US seller of estrogen patches alongside Viatris Inc. and Sandoz Group AG.
Earlier this month, Cinven Group Ltd., a private equity firm, announced plans to buy Theramex from The Carlyle Group Inc. and PAI Partners.
The takeaway for your portfolio
Demand is outrunning supply, regulators are weighing temporary importation, and a private equity-backed entrant is standing by with capacity. If the FDA opens the door, Theramex says it can move quickly with meaningful volumes, which could reshape share among current US suppliers. Watch three levers for impact on incumbents and would-be entrants alike - the FDA's stance on temporary imports, Theramex's planned 2027 filing, and Cinven's acquisition that could influence how aggressively Theramex builds a US footprint.
Learning how to use emerging technologies can quietly sharpen an investor's decision making. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.
